Briozzo P, Vignon F, Rochefort H
Unité Hormones et Cancer, INSERUM U 148, Montpellier.
Ann Endocrinol (Paris). 1989;50(3):175-80.
Synthetic antiestrogens are drugs commonly used in the endocrine therapy of breast cancer. Their pharmacology is complex, most of them presenting a partial estrogenic effect. Their action via the estrogen receptor (ER) has been better understood through the use of cellular models. The antihormone-ER complex binds to estrogen responsive elements on DNA, but is unable to mimic exactly the transcriptional activation induced by the estradiol-ER complex. The antiproliferative effect of these antihormones, mainly cystostatic but also cytotoxic, is the result of the competitive inhibition of estrogens, and might also involve interaction with other cellular mediators (stimulation of inhibitory factors, and growth factors inhibition). The term antiestrogen seems therefore to be too restrictive and it may be more accurate to name them estrogen-receptor mediated drugs inhibiting cell proliferation.
合成抗雌激素药物是乳腺癌内分泌治疗中常用的药物。它们的药理学很复杂,大多数都具有部分雌激素效应。通过细胞模型,人们对它们通过雌激素受体(ER)发挥的作用有了更好的理解。抗激素-ER复合物与DNA上的雌激素反应元件结合,但无法完全模拟雌二醇-ER复合物诱导的转录激活。这些抗激素的抗增殖作用主要是抑制细胞生长,但也有细胞毒性,是雌激素竞争性抑制的结果,也可能涉及与其他细胞介质的相互作用(刺激抑制因子和抑制生长因子)。因此,抗雌激素这个术语似乎过于局限,将它们命名为抑制细胞增殖的雌激素受体介导药物可能更准确。